Apple (NASDAQ: AAPL ) investors may already be on edge as of late, with the company's stock down about 20% from a year ago, and profit down over $2 billion this past quarter, year over year. Although Apple recently announced share repurchases, and boosted its dividend by 15%, many Apple stock investors aren't satisfied.
To top it all off, the latest numbers from Canalys show that Apple's arch rival, Samsung, shipped 82.2 million smart devices in Q1 2013, taking up 26.6% of the worldwide smart device market, while Apple took 19.3%. Surprisingly, Microsoft (NASDAQ: MSFT ) took the No. 3 spot with 18.1%, mainly becuase Canalys considers smart devices to be smartphones, tablets, and notebooks.
The numbers aren't exactly detrimental to Apple, but they should still concern investors. For a while, Apple held tablet and smartphone dominance, but its grip is starting to wane.
On the tablet front, Apple has lost some of it luster, but still maintains a 46.4% market share. The problem is that the iPad lost ground to�Android units for the third consecutive quarter, even while Apple's tablet sales have increased 65% from its previous quarter. The iPad Mini is driving the increased sales, but with the product already firmly in the market, its hard to imagine where Apple is going to make significant gains in tablet market share in the near future. The Mini's $329 price allows other companies to severely undercut Apple in price, and gobble up more market share.
Top 5 Tech Companies For 2015: iShares Transportation Average ETF (IYT)
iShares Dow Jones Transportation Average Index Fund (the Fund) seeks investment results that correspond generally to the price and yield performance of the Dow Jones Transportation Average Index (the Index). The Index measures the performance of the transportation sector of the United States equity market, and includes companies in primary groups, such as airlines, trucking, railroads, air freight, transportation services and industrial services.
The Index is subset of the Dow Jones U.S Total Market Index. The components stocks are weighted based on the price of the component securities, with the highest priced securities generally having higher weighting in the Index. The Index is adjusted to reflect changes in capitalization resulting from mergers, acquisitions, stock rights, substitutions and other capital events. The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. The Fund�� investment advisor is Barclays Global Fund Advisors.
Advisors' Opinion:- [By Gary Jakacky]
One of the real powerful forces behind this four and half year cyclical bull market has been the Dow Jones Transportation Average. After terrorizing "Dow Theorists" for nearly a year in 2012 by "refusing to confirm" new highs in the industrials, the Transports caught their second wind and ripped to new highs shortly after the new year began. A chart of the iShares Dow Jones Transportation ETF (IYT) shows this clearly. Since last January it has beaten back every attempt at a major correction:
Top 10 Rising Stocks To Watch For 2014: Cubist Pharmaceuticals Inc.(CBST)
Cubist Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. The company markets CUBICIN (daptomycin for injection), a once-daily, bactericidal, intravenous, antibiotic with activity against gram-positive organisms, including methicillin-resistant staphylococcus aureus. Its clinical development product pipeline consists of CXA-201, which is in the phase III clinical trial for patients with complicated urinary tract infections; and in phase II clinical trial for patients with complicated abdominal infections. The company is also developing CXA-201 for the treatment of hospital acquired pneumonia. In addition, its product under development comprises CB-183,315, an oral, bactericidal lipopeptide with in vitro bactericidal activity against C. difficile, for the treatment of clostridium difficile-associated diarrhea (CDAD). Further , the company?s pre-clinical programs include therapies to treat various bacterial infections and agents to treat acute pain. Additionally, it promotes MERREM I.V. (meropenem for injection), a carbapenem class intravenous antibiotic, in the United States under a commercial services agreement with AstraZeneca Pharmaceuticals, LP; and DIFICID as the treatment for CDAD in adults under the co-promotion agreement with Optimer Pharmaceuticals, Inc. The company also has collaborations with Forma Therapeutics, Inc. to discover and develop antibacterial compounds; an agreement with the Broad Institute to transform natural products discovery; a collaboration with Hydra Biosciences, Inc., to develop ion channel drugs; and a collaboration agreement with Alnylam Pharmaceuticals, Inc., for the development and commercialization of Alnylam's RNAi therapeutics as a therapy for the treatment of respiratory syncytial virus. The company was founded in 1992 and is headquartered in Lexington, Mas sachusetts.
Advisors' Opinion:- [By Sean Williams]
What: Shares of Cubist Pharmaceuticals (NASDAQ: CBST ) , a biopharmaceutical company devoted to developing acute care therapies, added 12% following the announcement of its second-quarter earnings results.
- [By Jake Keator]
Shares of Cubist Pharmaceuticals (NASDAQ: CBST ) exploded upward on Friday, finishing up over 9%. The company reported strong second-quarter results Thursday, beating average analyst estimates for both revenue and EPS. Total net revenues were $258.8 million, up 12.2% over Q2 2012, while non-GAAP diluted EPS was $0.42. Average analyst estimates were $254.73 million for revenue and EPS of $0.38.
- [By Victor Selva]
Forest Laboratories has a current ratio of 2.69% which is higher than the ones registered by Endo International Plc (ENDP), Valeant Pharmaceuticals International (VRX) and Cubist Pharmaceuticals Inc. (CBST). For investors looking for a higher ROE, Allergan Inc. (AGN) and Actelion Ltd. (ATLN.VX) are good options.
Top 10 Rising Stocks To Watch For 2014: Revlon Inc.(REV)
Revlon, Inc., through its subsidiaries, engages in manufacturing, marketing, and selling cosmetics, women?s hair color, beauty tools, anti-perspirant deodorants, fragrances, skincare, and other beauty care products worldwide. The company?s cosmetics include face makeup products, including foundation, powder, blush, concealers, bronzers, and finishers; lip makeup products comprising lipsticks, lip glosses, and lip liners; eye makeup products consisting of mascaras, eyeliners, eye shadows, and brow products; nail color and nail care products, such as enamels, treatments, and cuticle preparations; and face and eye makeup removers. Its beauty tools comprise nail, eye, and pedicure grooming tools, such as clippers, scissors, files, tweezers, eye lash curlers, and makeup brushes; and fragrances consist of perfumes, eau de toilettes, colognes, and body sprays. The company markets its products primarily under Revlon, Revlon ColorStay, Revlon Super Lustrous, Revlon Age Defying, A lmay Intense i-Color, Almay Smart Shade, Revlon ColorSilk, Mitchum, Charlie, Jean Nate, Ultima II, and Gatineau names. Revlon, Inc. sells its products through sales representatives and independent distributors to mass volume retailers, chain drug stores, chemist shops, hypermarkets, general merchandise stores, department stores; other specialty stores, such as perfumeries; and to the United States military exchanges and commissaries. It also licenses its brand names to third parties for the manufacture and sale of beauty-related products and accessories. The company was founded in 1932 and is based in New York, New York. Revlon, Inc. is a subsidiary of MacAndrews & Forbes Holdings Inc.
Advisors' Opinion:- [By Eric Volkman]
Revlon (NYSE: REV ) will need to have a serious discussion with its headhunters. The company revealed in an SEC filing that Executive Vice President and CFO Steven Berns has tendered his resignation. He has done so in order to take up the same positions at privately held media conglomerate Tribune Company.�
Top 10 Rising Stocks To Watch For 2014: Envision Healthcare Holdings Inc (EVHC)
Envision Healthcare Holdings, Inc., incorporated on February 28, 2011, is a provider of physician-led, outsourced medical services in the United States. The Company offers a range of clinically-based and coordinated care solutions across the patient continuum from medical transportation to hospital encounters to comprehensive care alternatives in various settings. The Company conduts its business primarily through two operating subsidiaries, EmCare Holdings, Inc. (EmCare) and American Medical Response, Inc. (AMR). The Company markets its services primarily under the EmCare and AMR brands. EmCareis a provider of integrated facility-based physician services, including emergency, anesthesiology, hospitalist/inpatient care, radiology, tele-radiology and surgery. EmCare also offers physician-led care management solutions outside the hospital. AMR is a provider and manager of community-based medical transportation services, including emergency (911), non-emergency, managed transportation, fixed-wing air ambulance and disaster response.
EmCare is a provider of integrated facility-based physician services to healthcare facilities, communities and payors in the United States. During the year ended December 31, 2012 (fiscal 2012), EmCare had approximately 10.5 million weighted patient encounters in 44 states and the District of Columbia. The Company segregates patient encounters into four categories:ED visits, hospitalist encounters, radiology reads and anesthesiology cases due to the differences in reimbursement rates for and associated costs of providing the various services. In fiscal 2012, AMR treated and transported approximately 2.8 million patients in 40 states and the District of Columbia. As of December 31, 2012, AMR had more than 3,700 contracts with communities, government agencies, healthcare providers and insurers to provide ambulance transport services. The Company segregates transports into two categories: ambulance transports (including emergency, as well as non-emergency, critical! care and other interfacility transports) and wheelchair transports to the differences in reimbursement rates for and associated costs of providing ambulance and wheelchair transports.
The Company competes with Team Health, Hospital Physician Partners, The Schumacher Group, Sheridan Healthcare, California Emergency Physicians, National Emergency Services Healthcare Group, IPC, Rural/Metro Corporation, Falck, Southwest Ambulance, Paramedics Plus and Acadian Ambulance.
Advisors' Opinion:- [By John Kell]
Envision Healthcare Holdings Inc.(EVHC) lowered its 2013 earnings outlook but also projected an adjusted profit for the recently started new year that topped expectations. The company said results improved in the latter part of the quarter, mostly the result of higher flu-related activity and seasonal volume. Shares rose 6.3% to $34.60 premarket.
Top 10 Rising Stocks To Watch For 2014: CardioNet Inc.(BEAT)
CardioNet, Inc. provides real-time ambulatory outpatient management solutions for monitoring clinical information regarding an individual's health to cardiologists and electro physiologists in the United States. The company focuses on the diagnosis and monitoring of cardiac arrhythmias through its Mobile Cardiac Outpatient Telemetry (MCOT) system, and event and Holter monitors. Its MCOT system is a real-time arrhythmia monitoring solution that incorporates a patient-worn sensor attached to leads, which captures ECG data and communicates wirelessly with a compact monitor that analyzes incoming information by applying proprietary algorithms and automatically transmits the ECG data to the CardioNet Monitoring Center, where cardiac monitoring specialists analyze the sent data and report results in the manner prescribed by the physician. The company also provides event monitoring services by using event monitors to record and store up to 540 seconds of ECG signal; Holter monito ring services by using Holter monitors to record a continuous ECG signal for one to two days; and pacemaker monitoring services for the periodic monitoring and evaluation of pacemakers implanted on patients. In addition, it engages in the development, manufacture, and marketing of medical devices and related software to medical companies, clinics, and hospitals. CardioNet, Inc. was incorporated in 1994 and is headquartered in Conshohocken, Pennsylvania.
Advisors' Opinion:- [By GuruFocus]
George Soros (Trades, Portfolio) just reported his first quarter portfolio. He buys Citrix Systems Inc, Baker Hughes Inc, Comcast Corp, Spansion Inc, etc during the 3-months ended 03/31/2014, according to the most recent filings of his investment company, Soros Fund Management LLC. As of 03/31/2014, Soros Fund Management LLC owns 305 stocks with a total value of $10.1 billion. These are the details of the buys and sells.New Purchases: BHI, CODE, CTRP, CLI, AVB, COMM, CNQ, AGO, AUY, ATML, ASH, BXMT, CSTM, AEM, CMA, ARE, CHKP, AUQ, BEAV, CX, ADSK, AALCP, BLK, AIG, BIIB, ADEP, AMRI, ARWR, ATHX, BALT, BCRX, BEAT, CFX, CLFD, CUR, CODE,Added Positions: CTXS, CMCSA, CNP, ALTR, BRCD, CBS, CRM, CHTR, CCJ, CIEN, BIDU, ALLE, ABT, CDNS, ACT,Reduced Positions: AAPL, CCI, AMT, ABBV, AAL, BITA, AL, ANGI, ARIA, CBST, BA, BIRT, EXAR,Sold Out: C, BAC, CRI, AMZN, AGN, CF, BRCM, COTY, BMY, AMCX, CAR, A, ADBE, AFL,For the details of George Soros (Trades, Portfolio)'s stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=George+SorosThis is the sector weightings of his portfolio:Technology18.9%Energy14%Healthcare8.3%Consumer Defensive8.2%Communication Services8.1%Consumer Cyclical5.4%Industrials5.1%Basic Materials4.9%Financial Services2.5%Real Estate1.9%Utilities0.5%These are the top 5 holdings of George Soros (Trades, Portfolio)1. Teva Pharmaceutical Industries Ltd (TEVA) - 10,310,041 shares, 5.4% of the total portfolio. Shares added by 10.67%2. Herbalife Ltd (HLF) - 4,901,337 shares, 2.8% of the total portfolio. Shares added by 52.9%3. EQT Corp (EQT) - 2,573,814 shares, 2.5% of the total portfolio. Shares added by 3.27%4. Adecoagro SA (AGRO) - 25,915,076 shares, 2.1% of the total portfolio.5. Halliburton Co (HAL) - 3,596,353 shares, 2.1% of the total portfolio. Shares reduced by 20.73%New Purchase: Baker Hughes Inc (BHI)George Soros (Trades, Portfolio) initiated holdings in Baker Hughes Inc. His purchase prices were between $51.82 and $65.27, with an estimated
Top 10 Rising Stocks To Watch For 2014: Methanex Corporation (MEOH)
Methanex Corporation, together with its subsidiaries, engages in the production, marketing, and sale of methanol. The company also purchases and re-sells methanol produced by others. Its methanol is a clear liquid commodity chemical that is used to produce traditional chemical derivatives, including formaldehyde, acetic acid, and various other chemicals. The company�s methanol is also used in energy-related applications; for blending into gasoline, as a feedstock in the production of dimethyl ether, which can be blended with liquefied petroleum gas for use in household cooking and heating, and in the production of biodiesel; and used to produce methyl tertiary-butyl ether, a gasoline component, as well as used into olefins applications. The company supplies its methanol to petrochemical producers and distributors in North America, the Asia Pacific, Europe, and Latin America. Methanex Corporation was founded in 1968 and is headquartered in Vancouver, Canada.
Advisors' Opinion:- [By Victor Selva]
The firm is currently Zacks Rank # 3��old, and it also has a longer-term recommendation of ��eutral�� A Hold rating indicates that the stock, over the next 1 to 3 months, will perform at an annualized rate of 10.56%, very similar to the S&P 500. For investors looking for a Zacks Rank # 1��trong Buy, Methanex Corporation (MEOH) could be the option.
Top 10 Rising Stocks To Watch For 2014: J. W. Mays Inc.(MAYS)
J.W. Mays, Inc. owns and operates commercial real estate properties in the United States. Its properties are located in Brooklyn, Jamaica, Levittown, Massapequa, and Fishkill, New York, as well as in Circleville, Ohio. The company was founded in 1924 and is based in Brooklyn, New York.
Advisors' Opinion:- [By Geoff Gannon] is trading around book value your next step is to figure out how book value is calculated.
The reason a company trading below book value is interesting has to do with accounting. In the U.S., you don�� mark up the book value of land and many other potentially valuable assets just because you have evidence ��like an appraisal, comparable sale, etc. ��that the market value is now higher than your original cost.
So, there will be situations where knowing how a company accounts for its assets and knowing the stock trades for less than book value can help direct you to companies selling for less than they are worth.
DreamWorks is a movie studio. So it is using a rather subjective estimate of the ultimate revenue a movie will produce. It is then amortizing the cost of the movie as revenue comes in to the company in proportion to the percentage of revenue this represents relative to expected total revenue the movie will produce.
For very old movies, it�� actually a little different. And for flops it�� different. DreamWorks can write off flops. And it can�� expect the ultimate revenue for a movie to be higher to the extent such revenue comes more than 10 years after the film�� release.
In other words, DreamWorks has to fully amortize a movie within 10 years and disregard the value an 11-year-old movie might have.
This is explained in a note to the company�� 10-K. It is very important for Ben Graham-type investors to read all these notes carefully ��but especially the notes on depreciation and amortization:
Once a film, television special/series or live performance is released, capitalized productions costs are amortized and participations and residual costs are accrued on an individual title basis in the proportion that the revenue during the period for each title (��urrent Revenue�� bears to the estimated remaining total revenue to be recognized from all sources for each title (��ltimate Revenue��. The amo
No comments:
Post a Comment